Study maps how tirzepatide's GIP receptor acts on human fat cells
New lab research on human fat cells describes a tirzepatide pathway that semaglutide does not use, though what it means for patients is not yet known.
Scientists have mapped how tirzepatide — the drug in Mounjaro and Zepbound — acts on human fat cells through a receptor that semaglutide (Ozempic, Wegovy and Rybelsus) does not touch [1].
The work, published in Cell Metabolism, comes from Regmi and colleagues [1]. The team studied the GIP receptor in human adipocytes, the medical term for fat cells, and looked at how switching that receptor on changes the way those cells take in and release energy [1].
The results describe what the authors call nutrient partitioning. When insulin was present, activating the GIP receptor increased the fat cells' uptake of glucose and lipids, the raw materials for storing energy [1]. When insulin was absent, turning on the same receptor pushed the cells toward lipolysis, the breakdown of stored fat [1]. In plain terms, the receptor appears to help fat cells decide whether to store energy or release it, depending on the hormonal signals around them [1].
Tirzepatide activates the GIP receptor for a long time, and it also activates the GLP-1 receptor [1]. Semaglutide works only through GLP-1. That difference is the focus of the paper: the GIP receptor offers a route into fat tissue that GLP-1 drugs cannot reach [1].
The findings come from laboratory experiments on cells, not from a trial in people. How much this cell-level behavior contributes to weight loss, blood sugar control or side effects in patients has not been reported [1]. The study does not provide a measure of weight change, and it does not compare tirzepatide with semaglutide in people [1]. The paper reports no patient safety data [1].
Why it matters for patients
Tirzepatide and semaglutide are often discussed as if they were variations of the same drug. At the receptor level, they are not [1]. Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and on GIP, and this paper describes what the GIP side does inside human fat cells [1].
Fat tissue is not just passive storage. It takes up and releases energy based on insulin signals, and this paper lays out one way a drug can influence that process [1]. Whether that helps explain why people respond differently to the two medicines is not yet known [1].
Nothing in the paper changes dosing, and it does not introduce new side effects or warnings for either drug [1]. Both remain prescription medicines, and the study does not suggest any change in how either is used [1].
What happens next
The paper does not report a timeline for follow-up research, and whether these findings will be tested in people has not been disclosed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.